Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tazemetostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 11,603Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hutchmed's NDA For Tazemetostat In Follicular Lymphoma Accepted In China
    Hutchmed's NDA For Tazemetostat In Follicular Lymphoma Accepted In China

    03 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/04/2908483/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Tazemetostat-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma-with-Priority-Review-Status.html

    GLOBENEWSWIRE
    03 Jul 2024
    Share Share
    CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance
    CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance

    29 Sep 2023

    // ONCLIVE

    https://www.onclive.com/view/cd38-48-upregulation-with-tazemetostat-may-overcome-daratumumab-resistance-in-multiple-myeloma

    ONCLIVE
    29 Sep 2023
    Share Share
    HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat
    HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat

    11 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/12/2741225/0/en/HUTCHMED-Completes-Patient-Enrollment-of-a-Bridging-Study-of-Tazemetostat-in-Patients-with-Relapsed-Refractory-Follicular-Lymphoma-in-China.html

    GLOBENEWSWIRE
    11 Sep 2023
    Share Share
    Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
    Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

    13 Aug 2022

    // PRESS RELEASE

    https://www.ipsen.com/press-releases/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology/

    PRESS RELEASE
    13 Aug 2022
    Share Share
    Epizyme Reports Second Quarter 2022 Financial Results
    Epizyme Reports Second Quarter 2022 Financial Results

    09 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220809005463/en

    BUSINESSWIRE
    09 Aug 2022
    Share Share
    Hutchmed begins dosing in follicular lymphoma therapy trial in China
    Hutchmed begins dosing in follicular lymphoma therapy trial in China

    01 Aug 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/hutchmed-follicular-lymphoma-therapy-trial/

    CLINICALTRIALSARENA
    01 Aug 2022
    Share Share